Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma

Jayprica Lilly

Share This Post

Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma.

In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobrutinib monotherapy that comprised 120 MCL patients who had previously received BTK inhibitor treatment, efficacy was assessed. Patients had received a median of three lines of therapy before, with 93% receiving two or more. Ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%), which were the most frequently prescribed prior BTK inhibitors, were stopped by 83% of patients due to refractory or worsening disease. Pirtobrutinib was given orally once day at a dose of 200 mg and continued until the disease progressed or the side effects became intolerable.

Overall response rate (ORR) and duration of response (DOR), as determined by an independent review committee using the Lugano criteria, were the primary efficacy measures. The ORR was 50% (95% CI: 41, 59) and 13% of respondents completed the survey in full. The estimated DOR rate at 6 months was estimated to be 65.3% (95% CI: 49.8, 77.1), and the estimated median DOR was 8.3 months (95% CI: 5.7, NE).

In patients with MCL, fatigue, musculoskeletal discomfort, diarrhoea, edoema, dyspnea, pneumonia, and bruising were the most frequent side effects (15%). Decreased neutrophil, lymphocyte, and platelet counts were grade 3 or 4 laboratory abnormalities in 10% of individuals. Precautions and warnings regarding infections, bleeding, cytopenias, atrial fibrillation and flutter, and second main malignancies are included in the prescribing material.

It is advised to take 200 mg of pirtobrutinib once daily until the disease progresses or the toxicity becomes intolerable.

 

View full prescribing information for Jaypirca.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy